Manhattan, New York, New York, May 30th, 2019 – Bridge Point Capital, a private equity firm based in New York City that specializes in U.S/China cross-border healthcare investments, is pleased to announce that Chuck Clarvit, CEO at CCFO Investments (the family office of Chuck Clarvit), will join the firm’s Advisory Board.
“We are thrilled to have Chuck join our Advisory Board,” said Mark Young, founding partner of Bridge Point Capital, “His unique experience as a successful strategic investor in the healthcare sector will help Bridge Point tremendously. His professional and personal affiliation with Johns Hopkins University will provide access to academicians and clinicians at a world-class medical research institution.”
Mr. Clarvit became CEO of his family office Clarvit Capital after retiring from Vinci Partners-US, an asset and wealth management firm headquartered in Brazil. He is a former Managing Director and Co-Head of BlackRock Alternative Advisors (“BAA”), the firm’s fund of funds platform. Mr. Clarvit held significant portfolio management responsibilities and oversaw marketing strategy and client service for the fund of funds business on the BAA platform.
Mr. Clarvit joined BlackRock in 2007 following the acquisition of the fund of funds business of Quellos Group, LLC. At Quellos, which managed over $31 billion dollars of client funds, he served as a Principal. He oversaw the Quellos Client Group and held significant portfolio management responsibilities.
By joining Bridge Point Capital‘s Advisory Board, Mr. Clarvit will contribute his unique insights on investment decisions based on years of successful experience in the capital markets. He will assist Bridge Point Capital’s due diligence investigations by providing access to preeminent scientists and doctors, as well as state-of-the-art medical technologies at Johns Hopkins University, where he is on the Board of Trustees.
Bridge Point Capital is a private equity firm based in New York with a focus on U.S.-China cross-border investment. We invest in disruptive late-stage healthcare companies that can benefit from penetrating the vast yet unexplored Chinese healthcare market. We aim to leverage our expertise in both healthcare and capital markets to establish a sustainable investment platform for our investors.